145 related articles for article (PubMed ID: 37423059)
21. Prognostic value of cell-free DNA in cerebrospinal fluid from lung cancer patients with brain metastases during radiotherapy.
Qiao S; Hao Y; Cai L; Duan X; Wang L; Zhou A; Zhu X
Radiat Oncol; 2023 Mar; 18(1):50. PubMed ID: 36906568
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
[TBL] [Abstract][Full Text] [Related]
23. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
Shi L; Guo L; Tao H; Meng Q; Tong L; Tang J; Li K; Zhang S; Liu Z
Thorac Cancer; 2023 Jul; 14(19):1883-1893. PubMed ID: 37287428
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.
Wu X; Xing P; Shi M; Guo W; Zhao F; Zhu H; Xiao J; Wan J; Li J
Front Oncol; 2022; 12():664420. PubMed ID: 35574310
[TBL] [Abstract][Full Text] [Related]
25. Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.
Xu Y; Huang Z; Yu X; Chen K; Fan Y
Mol Brain; 2021 Dec; 14(1):176. PubMed ID: 34952628
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis.
Chiang CL; Huang HC; Luo YH; Chiu CH
Front Biosci (Landmark Ed); 2021 Dec; 26(12):1679-1688. PubMed ID: 34994181
[TBL] [Abstract][Full Text] [Related]
27. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
28. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.
Xu Y; Hu M; Zhang M; Zhong W; Yin X; Sun Y; Chen M; Zhao J; Si X; Wang H; Zhang X; Zhang L; Li J; Guan H; Yang Z; Wang M
Lung Cancer; 2018 Nov; 125():142-149. PubMed ID: 30429013
[TBL] [Abstract][Full Text] [Related]
29. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
30. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
[TBL] [Abstract][Full Text] [Related]
31. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
32. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
34. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
35. Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.
Nie N; Zhou H; Zhang K; Liu L; Luo N; Wang R; Li X; Zhu M; Hu C; Wang Y; Liu Z; Li L; He Y
Thorac Cancer; 2022 Sep; 13(18):2574-2583. PubMed ID: 35896160
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
[TBL] [Abstract][Full Text] [Related]
37. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
38. Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.
Nian R; Jiang H; Zhao J; Hou W; Zhang H; Ma J; Lv P; Jiang L; Wang Y; Xu Y; Wu S; Lou J; Li W
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796015
[TBL] [Abstract][Full Text] [Related]
39. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
